AF
AVBP icon

Allworth Financial’s ArriVent BioPharma AVBP Stock Holding History

Allworth Financial’s Portfolio AVBP Stock Details AVBP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$1.84K Buy
53
+8
+18% +$236 ﹤0.01% 4539
2026
Q1 		$1.04K Buy
45
+27
+150% +$610 ﹤0.01% 4561
2025
Q4 		$363 Sell
18
-6
-25% -$125 ﹤0.01% 4605
2025
Q3 		$443 Sell
24
-99
-80% -$1.95K ﹤0.01% 4466
2025
Q2 		$2.68K Buy
123
+94
+324% +$1.95K ﹤0.01% 3579
2025
Q1 		$614 Buy
+29
New +$710 ﹤0.01% 3627

Other funds holding AVBP

SCM
Suvretta Capital Management New York $5.47B AUM 131.34% 1-Year Est. Return
IAM
Infinitum Asset Management Fort Lauderdale, Florida $983M AUM 26.53% 1-Year Est. Return
HA
HHLR Advisors Grand Cayman, Cayman Islands $832M AUM 32.38% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
OCA
Octagon Capital Advisors New York $1.11B AUM 866.76% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
SI
Sofinnova Investments Menlo Park, California $1.93B AUM 134.74% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

Allworth Financial's AVBP Position: Q2 2026 in Review

Allworth Financial increased its ArriVent BioPharma (AVBP) stake by 18% in Q2 2026, buying an estimated $236 and bringing the position to 53 shares worth $1.84K. The position accounts for ﹤0.01% of the portfolio, ranked #4539.

Allworth Financial first reported a position in AVBP in Q1 2025 and has held it in 6 quarters since. The position peaked at $2.68K in Q2 2025. 157 funds tracked by Wall St. Rank hold AVBP as of Q2 2026.

  • Allworth Financial held 53 shares of ArriVent BioPharma worth $1.84K as of Q2 2026.
  • Allworth Financial bought 8 ArriVent BioPharma shares in Q2 2026, an estimated $236.
  • ArriVent BioPharma made up ﹤0.01% of Allworth Financial's portfolio in Q2 2026, its #4539 holding.
  • Allworth Financial first reported a position in ArriVent BioPharma in Q1 2025 and has held it in 6 quarters since.
  • Allworth Financial's ArriVent BioPharma position peaked at $2.68K in Q2 2025.
  • 157 funds tracked by Wall St. Rank held ArriVent BioPharma as of Q2 2026.

Based on Allworth Financial's 13F filing for Q2 2026, filed 11 Aug 2026.